The global prevalence of mental health disorders has grown from an estimated 650 million in 1990 to 970 million in 2019. The COVID-19 pandemic exacerbated the issue, with rates of anxiety and depression increasing by 25% in the first year of the pandemic. In 2021, global sales of digital therapeutics for behavioral disorders were valued at approximately $625.0m.
Market drivers include the increasing prevalence of mental health disorders worldwide, the rapid expansion of telemedicine during the COVID-19 pandemic, increasing rates of internet access and smartphone penetration, positive regulatory changes for digital therapies, and the cost-effectiveness of digital therapy compared to traditional mental health systems. Limiters to this market include a lack of reimbursement for digital therapies in many world regions, difficulty monitoring patient compliance, slowed clinical trial progress during the COVID-19 pandemic, and the low priority of mental health globally.
This analysis includes a discussion of products, current/forecast markets, competitors, and opportunities in the global markets for behavioral health digital therapeutics; these include products intended to treat depressive disorder, stress/mild anxiety, anxiety disorder (including more severe conditions such as panic disorder and post-traumatic stress disorder), and substance use disorder (including alcohol and opioid addiction, among others). Countries covered by this report include the US, five major European markets (France, Germany, Italy, Spain, and the UK), Japan, and the Rest of World. The forecast range for this report is 2021-26.
Table of Contents
Executive Summary
i. Market forecast
- Exhibit ES-1: Digital therapeutics for behavioral health, combined market forecast ($m), by region, 2021-26
ii. Market drivers and limiters
iii. Market leaders
iv. Methodology
v. Bibliography
1. Overview of Digital Therapeutics for Behavioral Health
Exhibit 1-1: Prevalence of mental or substance use disorders, by country, 1990 and 2019
1.1 Depressive disorder
- Exhibit 1-2: Prevalence of depressive disorder, by country, 1990 and 2019
1.2 Stress
1.3 Anxiety disorder
- Exhibit 1-3: Prevalence of anxiety disorder, by country, 1990 and 2019
1.4 Substance use disorder
- Exhibit 1-4: Prevalence of alcohol abuse disorder, by country, 1990 and 2019
1.5 Bibliography
2. Digital Therapeutics for Behavioral Health
2.1 Behavioral health treatment techniques
2.1.1 Digital therapeutics and pharmaceuticals
2.1.2 Artificial intelligence
2.2 Regulation and reimbursement
2.2.1 US
- Regulation of mobile apps
- Software
- Digital Health Initiative
2.2.2 Europe
2.2.3 Japan
2.2.4 Global
2.3 Clinical trials
2.4 Digital therapeutics for depressive disorder
2.4.1 HelloBetter
2.4.2 Orexo
2.4.3 Limbix Health
- Exhibit 2-1: Selected digital therapeutics for depressive disorder, 2022
2.4.4 Emerging technologies
2.5 Digital therapeutics for stress/mild anxiety
2.5.1 BehaVR
2.5.2 Calm Health
2.5.3 Livongo Health/Teladoc Health
- Exhibit 2-2: Selected digital therapeutics for stress/mild anxiety, 2022
2.5.4 Emerging technologies
2.6 Digital therapeutics for anxiety disorder
2.6.1 Freespira
2.6.2 HelloBetter
2.6.3 Nightware
- Exhibit 2-3: Selected digital therapeutics for anxiety disorder, 2022
2.7 Digital therapeutics for substance use disorder
2.7.1 HelloBetter
2.7.2 Orexo
2.7.3 Pear Therapeutics
2.7.4 SilverCloud/Amwell
- Exhibit 2-4: Selected digital therapies for substance use disorder, 2022
2.7.5 Emerging technologies
2.8 Bibliography
3. Digital Therapeutics for Behavioral Health Market
3.1 Global market analysis
- Exhibit 3-1: Digital therapeutics for behavioral health, combined market forecast ($m), by region, 2021-26
- Exhibit 3-2: Digital therapeutics for behavioral health, combined market forecast ($m), by product segment, 2021-26
3.1.1 Market drivers and limiters
3.1.2 Market leaders and competitive strategies
- Headspace Health
- Wysa
- SilverCloud
- Twill
- Pear Therapeutics
- Other suppliers
- Exhibit 3-3: Digital therapeutics for behavioral health market, share by supplier, 2021
3.1.3 Emerging competition
3.2 Regional trends
3.2.1 US
3.2.2 Five major European markets
3.2.3 Japan
3.2.4 Rest of world
3.3 Market forecast
3.3.1 Digital therapeutics for depressive disorder, market forecast
- Exhibit 3-4: Digital therapeutics for depressive disorder, market forecast, by region ($m), 2021-26
- Competitive analysis
- Exhibit 3-5: Digital therapeutics for depressive disorder, share by supplier, 2021
3.3.2 Digital therapeutics for stress/mild anxiety, market forecast
- Exhibit 3-6: Digital therapeutics for stress/mild anxiety, market forecast, by region ($m), 2021-26
- Competitive analysis
- Exhibit 3-7: Digital therapeutics for stress/mild anxiety, share by supplier, 2021
3.3.3 Digital therapeutics for anxiety disorder, market forecast
- Exhibit 3-8: Digital therapeutics for anxiety disorder, market forecast, by region ($m), 2021-26
- Competitive analysis
- Exhibit 3-9: Digital therapeutics for anxiety disorder, share by supplier, 2021
3.3.4 Digital therapeutics for substance use disorder, market forecast
- Exhibit 3-10: Digital therapeutics for substance use disorder, market forecast, by region ($m), 2021-26
- Competitive analysis
- Exhibit 3-11: Digital therapeutics for substance use disorder, share by supplier, 2021
3.4 Bibliography
- Company Listing
Companies Mentioned
- BehaVR
- Calm Health
- Freespira
- Headspace Health
- HelloBetter
- Limbix Health
- Livongo Health/Teladoc Health
- Nightware
- Orexo
- Pear Therapeutics
- SilverCloud/Amwell
- Twill
- Wysa
